William A. Jones Jr.
CIK: 0001373097
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Sep 3, 2026APGE
Apogee Therapeutics, Inc.
Disposition(D)Direct34.8K shares- - Aug 3, 2026APMD
Apnimed, Inc.
Award(A)DirectStock Option (Right to Buy)
44.5K shares- - Aug 3, 2026APMD
Apnimed, Inc.
Disposition(D)DirectStock Option (Right to Buy)
44.5K shares- - Jul 30, 2026APMD
Apnimed, Inc.
Award(A)DirectStock Option (Right to Buy)
44.5K shares- - Jun 11, 2026ANNX
Annexon, Inc.
Award(A)DirectStock Option (Right to Buy)
65K shares- - Jun 9, 2026APGE
Apogee Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
7.7K shares- - Jun 17, 2025APGE
Apogee Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
14.5K shares- - Jun 5, 2025ANNX
Annexon, Inc.
Award(A)DirectStock Option (Right to Buy)
55K shares- - Jan 9, 2025ANNX
Annexon, Inc.
Award(A)DirectStock Option (Right to Buy)
88K shares- - Jan 7, 2025NAMS
NewAmsterdam Pharma Co N.V.
Award(A)Direct43K shares- - Jan 2, 2025NAMS
NewAmsterdam Pharma Co N.V.
Award(A)DirectOption (right to buy)
200K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 3, 2026 |  APGE Apogee Therapeutics, Inc. | Disposition(D) | 34,824 | - | $0 | Direct |
| Aug 3, 2026 |  APMD Apnimed, Inc. | Award(A) Stock Option (Right to Buy) | 44,477 | - | - | Direct |
| Aug 3, 2026 | APMD Apnimed, Inc. | Disposition(D) Stock Option (Right to Buy) | 44,477 | - | - | Direct |
| Jul 30, 2026 | APMD Apnimed, Inc. | Award(A) Stock Option (Right to Buy) | 44,477 | - | - | Direct |
| Jun 11, 2026 |  ANNX Annexon, Inc. | Award(A) Stock Option (Right to Buy) | 65,000 | - | - | Direct |
| Jun 9, 2026 | APGE Apogee Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 7,657 | - | - | Direct |
| Jun 17, 2025 | APGE Apogee Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 14,461 | - | - | Direct |
| Jun 5, 2025 | ANNX Annexon, Inc. | Award(A) Stock Option (Right to Buy) | 55,000 | - | - | Direct |
| Jan 9, 2025 | ANNX Annexon, Inc. | Award(A) Stock Option (Right to Buy) | 88,000 | - | - | Direct |
| Jan 7, 2025 |  NAMS NewAmsterdam Pharma Co N.V. | Award(A) | 43,000 | - | $0 | Direct |
| Jan 2, 2025 | NAMS NewAmsterdam Pharma Co N.V. | Award(A) Option (right to buy) | 200,000 | - | - | Direct |
1-11 of 11 transactions
About JONES WILLIAM A JR
JONES WILLIAM A JR (SEC CIK 0001373097) files insider reports with the SEC as Director of Apogee Therapeutics, Inc. (APGE), Director of Apnimed, Inc. (APMD) and Director of Annexon, Inc. (ANNX). Signal8 also holds filings tied to 1 other company.
Signal8 holds 11 ownership filings by JONES WILLIAM A JR (2 Form 3, 9 Form 4), filed between Jan 6, 2025 and Sep 3, 2026. Those filings report 11 transactions, from Jan 2, 2025 to Sep 3, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on JONES WILLIAM A JR's filings is in SAN FRANCISCO, CA.
Recent filings by JONES WILLIAM A JR
- Sep 3, 2026: Disposition to issuer transaction of APGE shares (Form 4, code D).
- Aug 3, 2026: Grant or award of APMD derivative securities (Form 4, code A).
- Aug 3, 2026: Disposition to issuer transaction of APMD derivative securities (Form 4, code D).
- Jul 30, 2026: Grant or award of APMD derivative securities (Form 4, code A).
- Jun 11, 2026: Grant or award of ANNX derivative securities (Form 4, code A).
Other insiders filing for Apogee Therapeutics, Inc. (APGE)
- Fairmount Funds Management LLC, Director
- McKenna Mark C., Director
- Dambkowski Carl, Chief Medical Officer
- Fox Jennifer A., Director
- Henderson Jane, Chief Financial Officer
- Bollinger Lisa, Director